Richmond Chemical Corporation

Oak Brook, IL 60523

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $1.04MM
First Award Date 08/01/07
Most Recent Award Date 06/01/10

Key Personnel

Last Name Name Awards Contact
Taylor Paul Phillip Taylor 4

4 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 06/01/10 - 05/31/11

DESCRIPTION (provided by applicant): Unnatural amino acids represent one of the largest and growing classes of intermediates used by the pharmaceutical, agrochemical and fine chemical industries. Demand for these compounds at large scale and high optical purity is now very significant, due to their application and success in single enantiomer ph...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 08/01/09 - 05/31/10

DESCRIPTION (provided by applicant): Unnatural amino acids represent one of the largest and growing classes of intermediates used by the pharmaceutical, agrochemical and fine chemical industries. Demand for these compounds at large scale and high optical purity is now very significant, due to their application and success in single enantiomer ph...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-20
Budget: 09/01/07 - 02/29/08

DESCRIPTION (provided by applicant): In 1970 5% of licensed pharmaceuticals contained at least one fluorine atom. In 2005 this figure had risen dramatically to 20% and it is now estimated that 25% of current pipeline drugs now contain at least one fluorine atom. The importance of fluorine to pharmaceutical discovery and functionality cannot be o...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-20
Budget: 08/01/07 - 01/31/08

DESCRIPTION (provided by applicant): Unnatural amino acids represent one of the largest classes of intermediates used by the pharmaceutical, agrochemical and fine chemical industries. Demand for these compounds at large- scale and high optical purity is now very significant, due to their application in single enantiomer pharmaceuticals, particul...